XML 82 R66.htm IDEA: XBRL DOCUMENT
v3.21.2

Goodwill and Other Intangible Assets (Details) $ in Thousands |  |  |  |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Apr. 12, 2021 USD ($) | Mar. 19, 2021 USD ($) | Feb. 14, 2020 USD ($) item product | Nov. 01, 2019 product | Mar. 19, 2019 | Mar. 31, 2021 USD ($) | Jun. 30, 2018 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2020 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Impairment of intangible assets, finite-lived |  |  |  |  |  |  |  | $ 12,825 | $ 195
Finite-lived intangible assets, net carrying amount |  |  |  |  |  |  |  | 82,864 | 48,855
Amortization of intangible assets |  |  |  |  |  |  |  | 6,009 | 4,490
Total amortization expense |  |  |  |  |  |  |  | 7,100 | 4,500
Goodwill acquired |  |  |  |  |  |  |  | $ 37,712 | 28,090
Number of products acquired | product |  |  |  | 4 |  |  |  |  |
Minimum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived intangible asset, period before next renewal or extension (years) |  |  |  |  |  |  |  | 1 year |
Maximum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived intangible asset, period before next renewal or extension (years) |  |  |  |  |  |  |  | 20 years |
Neos Therapeutics, Inc. |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Goodwill acquired |  |  |  |  |  |  |  | $ 37,700 |
Acquired intangible assets |  | $ 2,600 |  |  |  |  |  |  |
Acerus |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Termination agreement, aggregate amount |  |  |  |  |  | $ 7,500 |  |  |
Termination agreement, equal monthly installment payment, period |  |  |  |  |  | 30 months |  |  |
Karbinal ER |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Optional initial extension term (years) |  |  |  |  |  |  |  | 20 years |
Licensed assets |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net carrying amount |  |  |  |  |  |  |  | $ 1,816 | 16,587
Estimated useful lives (in years) |  |  |  |  |  |  |  | 7 years |
Licensed assets | Natesto |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Impairment of intangible assets, finite-lived |  |  |  |  |  |  |  | $ 4,300 |
Finite-lived intangible assets, net carrying amount |  |  |  |  |  |  |  | 0 |
Licensed assets | ZolpiMist |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Acquired intangible assets |  |  |  |  |  |  | $ 3,200 |  |
Licensed assets | ZolpiMist | Maximum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Estimated useful lives (in years) |  |  |  |  |  |  | 7 years |  |
Licensed assets | Tuzistra XR. |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Impairment of intangible assets, finite-lived |  |  |  |  |  |  |  | 8,500 |
Product Technology Right |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net carrying amount |  |  |  |  |  |  |  | 41,240 | 21,187
Acquired intangible assets |  |  |  |  |  |  |  | $ 45,400 |
Product Technology Right | Minimum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Estimated useful lives (in years) |  |  |  |  |  |  |  | 10 years |
Product Technology Right | Maximum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Estimated useful lives (in years) |  |  |  |  |  |  |  | 17 years |
Product Technology Right | ADHD Portfolio |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Estimated useful lives (in years) |  |  |  |  | 17 years |  |  |  |
Developed technology right |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net carrying amount |  |  |  |  |  |  |  | $ 29,699 |
Estimated useful lives (in years) |  |  |  |  |  |  |  | 17 years |
Developed technology right | Neos Therapeutics, Inc. |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Acquired intangible assets |  | $ 30,200 |  |  |  |  |  |  |
Estimated useful lives (in years) |  | 17 years |  |  |  |  |  |  |
Product distribution rights |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net carrying amount |  |  |  |  |  |  |  | $ 9,281 | 10,789
Product distribution rights | Minimum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Estimated useful lives (in years) |  |  |  |  |  |  |  | 5 years |
Product distribution rights | Maximum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Estimated useful lives (in years) |  |  |  |  |  |  |  | 10 years |
Product distribution rights | Innovus |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Acquired intangible assets |  |  | $ 11,400 |  |  |  |  |  |
Product distribution rights | Innovus | Minimum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Estimated useful lives (in years) |  |  | 3 years |  |  |  |  |  |
Product distribution rights | Innovus | Maximum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Estimated useful lives (in years) |  |  | 10 years |  |  |  |  |  |
Commercial technology |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net carrying amount |  |  |  |  |  |  |  | $ 452 |
Estimated useful lives (in years) |  |  |  |  |  |  |  | 2 years |
Commercial technology | Neos Therapeutics, Inc. |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Acquired intangible assets |  | $ 600 |  |  |  |  |  |  |
Estimated useful lives (in years) |  | 1 year |  |  |  |  |  |  |
Trade name |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net carrying amount |  |  |  |  |  |  |  | $ 344 |
Estimated useful lives (in years) |  |  |  |  |  |  |  | 1 year |
Trade name | Neos Therapeutics, Inc. |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Acquired intangible assets |  | $ 400 |  |  |  |  |  |  |
Estimated useful lives (in years) |  | 2 years |  |  |  |  |  |  |
Customer lists |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net carrying amount |  |  |  |  |  |  |  | $ 32 | $ 292
Estimated useful lives (in years) |  |  |  |  |  |  |  | 1 year 6 months |
Customer lists | Innovus |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Acquired intangible assets |  |  | $ 400 |  |  |  |  |  |
Estimated useful lives (in years) |  |  | 1 year 6 months |  |  |  |  |  |
Product distribution rights and customer list | Innovus |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of products acquired | product |  |  | 35 |  |  |  |  |  |
Registered trademarks | item |  |  | 300 |  |  |  |  |  |
Rumpus | In-process R&D |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Up-front fee | $ 1,500 |  |  |  |  |  |  |  |
Payment of aggregated fees | $ 600 |  |  |  |  |  |  |  |

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References No definition available. + Details
Name: | aytu_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of consideration transferred for transaction cost incurred in asset acquisition. + References No definition available. + Details
Name: | aytu_AssetAcquisitionConsiderationTransferredForTransactionCost
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | aytu_FiniteLivedIntangibleAssetPeriodBeforeNextRenewalOrExtension
Namespace Prefix: | aytu_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of products acquired. + References No definition available. + Details
Name: | aytu_NumberOfProductsAcquired
Namespace Prefix: | aytu_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of trademarks and or patent rights and customer lists obtained. + References No definition available. + Details
Name: | aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired
Namespace Prefix: | aytu_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Optional extension term under supply and distribution agreement. + References No definition available. + Details
Name: | aytu_SupplyAndDistributionAgreementOptionalExtensionTerm
Namespace Prefix: | aytu_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents aggregate amount of termination agreement. + References No definition available. + Details
Name: | aytu_TerminationAgreementAggregateAmount
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents equal monthly installment payment period for termination agreement. + References No definition available. + Details
Name: | aytu_TerminationAgreementEqualMonthlyInstallmentPaymentPeriod
Namespace Prefix: | aytu_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total amount of amortization expense including the amount included in cost of sales. + References No definition available. + Details
Name: | aytu_TotalAmortizationOfIntangibleAssets
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillAcquiredDuringPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=aytu_NeosTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=aytu_AcerusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=aytu_KarbinalErMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_LicensedAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=aytu_ZolpimistMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=aytu_TuzistraXr.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=aytu_AdhdPortfolioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductDistributionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_CommercialTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductDistributionRightsAndCustomerListMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | aytu_AssetAcquisitionAxis=aytu_RumpusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |